Every once in a while, an advance in treating cancer is so stunning that doctors get chills. Such is the case for Revolution Medicines’ pancreatic cancer therapy daraxonrasib, which in a late-stage study allowed patients with advanced disease to live twice as long as those who only received chemotherapy.